Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

Diabetes Care

Volumn 31, Issue 8, 2008, Pages 1479-1484

  Fonseca, Vivian A ^a   Rosenstock, Julio ^b   Wang, Antonia C ^c   Truitt, Kenneth E ^c   Jones, Michael R ^c  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; COLESEVELAM; FRUCTOSAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; ALLYLAMINE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; AGED; BLOOD; BODY MASS; DRUG COMBINATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; SULFONYLUREA COMPOUNDS;

EID: 49649095014     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0283     Document Type: Article

References (23)

1. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
6. American Diabetes Association: Standards of medical care in diabetes-2007. Diabetes Care 30 (Suppl. 1):S4-S41, 2007
7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and micro- vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
8. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2:120-126, 1979
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
10. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
11. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
13. Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG: The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 28:1029-1034, 2005
14. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL: Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29:74-83, 2007
15. Goldberg RB, Fonseca VA, Truitt KE, Jones MR: Efficacy and safety of colesevelam hydrochloride in patients with type 2 diabetes mellitus with inadequate glycemic control on insulin-based therapy. Arch Intern Med, in press
16. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9:733-745, 2007
17. Wallace TM, and Matthews DR: Coefficient of failure: a methodology for examining longitudinal beta-cell function in type 2 diabetes. Diabet Med 19:465-469, 2002
18. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'Connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL: Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99:56i-67i, 2007
19. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Mer- rifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687-1697, 2007
20. Garg A, and Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a shortterm, double-blind, crossover trial. Ann Intern Med 121:416-422, 1994
21. Guzelian P, and Boyer JL: Glucose reabsorption from bile: evidence for a biliohepatic circulation. J Clin Invest 53:526-535, 1974
22. Chiang JY, Kimmel R, Weinberger C, Stroup D: Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Biol Chem 275:10918-10924, 2000
23. Saydah SH, Fradkin J, and Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342, 2004